Stable’s Post

🌟 Empowering Biotech Innovation: MSInsight x Capital Cell 🌍 At MSInsight, we're committed to accelerating life sciences breakthroughs that can potentially transform global cancer care. Our partnership with Capital Cell, Europe’s first equity crowdfunding platform dedicated to biotech, is a crucial step in achieving this mission. This collaboration is not just about raising capital; it's about connecting with a community of passionate investors who share our vision for healthcare innovation. 💡 Why Capital Cell? Capital Cell is redefining biotech investment by making it accessible to a broader audience. No longer limited to institutional investors, this platform allows anyone to invest in early-stage, high-impact biotech companies. This democratization aligns perfectly with one of our goals at MSInsight: to engage diverse investors in advancing life-altering technologies. 🚀 The Impact of Our Partnership Through Capital Cell, we’re securing essential funding for our projects and building a network of advocates who believe in the future of healthcare. Together, we’re pushing the boundaries of what’s possible in biotech, driving solutions that can profoundly impact global cancer care outcomes. Join us on this exciting journey as we continue to innovate and bring cutting-edge biotech solutions to the market, supported by Capital Cell and our growing community of over 110 investors. https://lnkd.in/d9aBcVPi #Biotech #Investment #CapitalCell #MSInsight #Crowdfunding #LifeSciences #HealthcareInnovation https://lnkd.in/dh4JaEaw

Recently, I had the privilege of attending an insightful update session led by the CEO of a cutting-edge medical company I invested in back in 2021. This company, specializing in groundbreaking cancer treatments and solutions for other diseases, has shown remarkable progress and innovation. During the session, not only did we witness a compelling demonstration of their advancements, but we also learned about the company's strategic move towards raising an additional 10 crores at a 100 crore valuation in a demerged entity. This pivotal moment has presented me, alongside fellow investors, with a golden opportunity to further invest at this increased valuation, courtesy of an offer extended by CEO to the investors. The dilemma that now stands before me is whether to seize this chance to augment my stake in a domain where genuine innovation is making waves or to diversify my portfolio by nurturing new ventures in their nascent stages. The growth from an initial valuation of 60 crores to a substantial 100 crores that too in the a part of the demerged company is not just numerical; it's a testament to the company's potential and the hard work behind it. After much contemplation, my inclination leans towards protecting and potentially increasing my share in the company. The rationale is straightforward: amidst the myriad of investments, only a select few demonstrate the capability to secure successive funding rounds. These are the true stars in a portfolio, promising not just returns but also contributing to significant advancements in their respective fields. As I ponder over this decision, I invite my network to share their insights and experiences. How do you approach such crossroads in investments? Do you prioritize the growth of your existing stakes in high-performing companies, or do you believe in the potential of diversifying by backing new entrants? Your perspectives could shed light on the multitude of strategies that seasoned investors employ, helping not just me but others in our community to navigate similar paths. #InvestmentDecisions #GrowthStrategy #MedicalInnovation #StartupInvesting #VentureCapital

We're seeing seismic shifts in how many investors think about private markets. This is something we track closely at BIP Capital as we work to bring premium private investment products to the market and make them accessible for more accredited investors. We see incredible value being built among companies in the private market, but in many ways the private markets can feel like a black box to people. This is precisely why we have created these short, educational webinars about private marketing investing and diversifying investment portfolios with the additions of select alternative investment products. The goal of these webinars is to empower investors and interested professionals to know what to look for in private market products and managers and what the world of alternative investments looks like. Whether you're interested in potentially participating in private market investing one day or you're simply seeking to learn more about the space, I hope you'll join us next Wednesday, September 11th at 2PM EST. Register here: https://lnkd.in/e4Zbv3zr

Great session and appreciated being able to see the recording. Thanks for standing in for me Laurent Jacqueroud. Your contribution was fantastic. Key themes of following the science, the need for experienced teams to leverage commercial success, the need to focus on products not just science ( ie unmet medical need and rapid incorporation of new therapies into standard treatment paradigms) and the power of partnerships were all spot on. Also appreciated the comments by Edward Van Wezel about the need for early stage data to support scientific hypotheses and how even at the earlier stages of development, strong data packages can support the ability to pick the winners. Company build models are optimum enablers of this approach. They ensure an enrichment of the strongest science and most commercially viable projects as early as possible. The approach is most powerfully executed when managed by a team of experienced operators. Pretty much sums up Cumulus Oncology Oncology https://lnkd.in/d_3BMDbC

Capital Cell has just launched another funding campaign, this time for Hemerion Therapeutics, a French clinical-stage company developing a fascinating new treatment for #glioblastoma. The treatment combines a photosensitive #drug with a photonic #medicaldevice, and can be incorporated into the standard surgical protocol for glioblastoma. To check out this and the other seven #biotechcompanies currently raising funds through Capital Cell, visit our #investmentopportunities page: https://lnkd.in/dKgEz_bJ #biotechinvestment #biotechnology #investment #lifescienceinvestment #earlystageinvestment #biotech #cancer #cancertreatment

💵 How does a startup get the capital it needs? ⁉ One way for early-stage startups to secure funding is through angel investors. The Life Science Angels is a distinguished group of over 150 investors dedicated to Bio Pharma and Medical & Health Technology. The process: Startups apply and undergo an initial screening by our fellows. Selected companies are then invited to pitch to the screening committee. Based on member interest, we conduct thorough due diligence, and two companies are invited to present at our quarterly dinner. Real-world example: At LSA's upcoming 2nd quarter dinner on 6/19, we are thrilled to host iSono Health, creators of an *** automated and portable *** ultrasound system for breast cancer detection, particularly beneficial for women with dense breast tissue. We look forward to hearing from CEO Neda Razavi, MBA about their progress and future plans, including AI capabilities and their launch strategy. The outcome: Breast cancer detection must be improved, and innovative companies like iSono are stepping up to the challenge. Angel investors play a crucial role in supporting these pioneering entrepreneurs and advancing the healthcare ecosystem. Join us: If you are passionate about med tech innovation and investing in the future of healthcare, learn more about LSA and how you can get involved. https://lnkd.in/g-_yjgEp #AngelInvesting #StartupFunding Chris Neil Sammy Datwani, Ph.D Mary G. Allan May Eugene Dariush Daneshvar Women's Health PAC

For investors interested in our Q2 roadshow covering New York, Boston, Princeton, Chicago, San Diego, and San Francisco, BIORCHESTRA Co., Ltd.'s #RNAi update covers: ✨ In-vivo progress on our neurodegenerative diseases franchise and proprietary IV-formulated RNAi research in #Alzheimer's and #Parkinson's ✨ Status of our #ALS program FDA IND pathway  ✨ Licensing negotiations in #CNS, #INHBE/ #MAFLD, and #Glaucoma ✨ Our bridge round syndicate and NYSE / NASDAQ pathway timing To those requesting one-on-ones through LinkedIn, email [email protected] for slots. Bramalea Partners, PJT Partners, Perella Weinberg, William Blair Investment Banking, Jefferies, Leerink Partners, Nomura, Cain Brothers, CITIC Securities Company Limited, CITIC CLSA Forums, UBS, Oppenheimer & Co. Inc., Wells Fargo Corporate & Investment Banking, Mikael Dolsten Guggenheim Partners, Outcome Capital, Brian Doyle, Michael Bardi, Michael Zhang, Veet Misra, Cantor Fitzgerald, Noël Brown, Samuel Siu, CPA, RBC Capital Markets, John C. Reed, Novo Holdings, Lilly Asia Ventures 礼来亚洲基金, Richard A. Gonzalez, Sumitomo Mitsui Banking Corporation – SMBC Group, #pfizercolleague, Centerview Partners, Morgan Stanley USA, Citi, Bank of America Business, Greenhill & Co., Evercore, Rothschild & Co., Moelis & Company, New York Stock Exchange, Nasdaq Exchange

Always nice to be able to contribute a blog to our own One Nucleus site. This time I was reflecting on activities past, present and future being done to increase our members' investment opportunities in my article 'Boston & Beyond' https://lnkd.in/eskK2EEp included in the latest eNews. To check out what else was covered in the newsletter visit https://lnkd.in/eappyWBj

𝐖𝐡𝐚𝐭’𝐬 𝐭𝐡𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐜𝐚𝐬𝐞? - Part 5 We began by refining Maya’s opening. The hook was critical—it needed to immediately capture the room’s attention. “Imagine a world where a child born with a genetic disorder can live a life free from limitations,” she began. The statement was simple but powerful, perfectly setting the stage for the story of GeneQuest’s mission. During rehearsals, we worked on pacing, tone, and transitions between sections. Each member of the team practiced their part, ensuring a seamless flow of information from problem statement to solution, market opportunity, and financials. One of the biggest challenges was tackling the Q&A session. Investors would not hold back on tough questions, probing for weaknesses in the business model, market strategy, and technology itself. To prepare, I conducted a role-playing exercise where I assumed the role of a skeptical investor, pushing Maya and her team to defend their projections, pricing strategies, and scalability plans. While the process was rigorous, it built their confidence and sharpened their ability to respond under pressure. The day of the pitch arrived. As I waited with Maya and Alex in the green room, the weight of the moment was palpable. Maya took a deep breath before stepping into the boardroom, where a dozen seasoned investors sat waiting. She began with the hook, her voice steady and clear, and immediately captured their attention. The narrative flowed smoothly, each slide building upon the last to tell a story of immense potential and a clear plan to achieve it. When Maya presented the market opportunity, the room leaned in. The numbers spoke for themselves—a $20 billion market with a clear entry point through rare disease clinics. The visual matrix we had developed to showcase GeneQuest’s differentiation drew nods of approval. As Maya outlined the financial projections and subscription-based pricing model, the investors’ questions began, just as we had anticipated. One investor questioned the scalability of the business model, particularly in international markets. Maya confidently explained how the subscription approach reduced financial barriers for clinics, making it adaptable across different regions. Another asked about regulatory hurdles, and the team highlighted their advisory board’s expertise in navigating these challenges. Their preparation was evident, and each response reinforced GeneQuest’s credibility. The pitch concluded with Maya’s closing statement: “GeneQuest is not just an investment in technology; it’s an investment in changing lives.” The room was silent for a moment, then filled with the buzz of investors discussing what they had just heard. Maya had not only delivered the facts but also the passion behind her team’s mission.